Yalin Zhu

Yalin Zhu

Central US Merck & Co., Inc. - Kenilworth / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 5186150
-
person_outline Yalin Zhu's MOST POPULAR ARTICLES
1-) Event-free survival by residual cancer burden after neoadjuvant pembrolizumab+ chemotherapy versus placebo+ chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.L Pusztai, C Denkert, J O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Shaughnessy, J Cortes, RA Dent, HL McArthur, ...Journal of Clinical Oncology 40 (16_suppl), 503-503, 2022432022
2-) Application of a novel mass spectrometric (MS) method to examine exposure to Bisphenol-A and common substitutes in a maternal fetal cohortES Ihde, S Zamudio, JM Loh, Y Zhu, J Woytanowski, L Rosen, M Liu, ...Human and Ecological Risk Assessment: An International Journal 24 (2), 331-346, 2018242018
3-) Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522L Pusztai, C Denkert, J O’Shaughnessy, J Cortes, R Dent, H McArthur, ...Annals of Oncology 35 (5), 429-436, 2024132024
4-) Family-wise error rate controlling procedures for discrete dataY Zhu, W GuoStatistics in Biopharmaceutical Research 12 (1), 117-128, 2020112020
5-) Abstract PD3-01: Neoadjuvant pembrolizumab+ chemotherapy vs placebo+ chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant …H McArthur, J Cortés, R Dent, J O’Shaughnessy, L Pusztai, S Küemmel, ...Cancer Research 83 (5_Supplement), PD3-01-PD3-01, 202352023